Publication Details
Abstract
Among ocular diseases, AMD is one of the major causes leading to visual loss in elderly population and has high rate of impact on quality of life. Effective treatment is challenging, even as therapeutic options evolve while The objective of the present study is to assess our progress in AMD management focusing on the efficacy, visual acuity results, compliance data, and overall health-related quality of life and collected in our study One hundred and six patients with a diagnosis of AMD were reviewed after 1 year in various hospitals in Iraq between 2024 and 2025. We evaluated VA, treatment methods, and complications as well as QOL in questionnaires and eye checkups as well as Visual acuity gain post treatment was substantial with 37.7% gaining to 20/20. The most frequent were anti-VEGF injections (56.6%). Compliance was very good, 56.6 percent were absolutely compliant. Satisfaction among patients was high, with the majority achieving significant gains in the quality of their life so finally Progress in the treatment of AMD, and especially with anti-VEGF therapy, has been reflected in better visual outcome and patient satisfaction. Patient education and compliance are critical to optimizing treatment results.